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Abstract
Background: The aim of this study is to evaluate the presence of neurocognitive dysfunctions, depression and
anxiety and the effect of positive airway pressure (PAP) therapy on these alterations in Obesity Hypoventilation
Syndrome (OHS) patients.
Methods: Ten healthy normal and obese controls, 10 OHS and 10 OSAS patients were included in the study. Short
form-36, Beck Depression Scale and State-Trade Anxiety Inventory (STAI 1-2) were performed. Wisconsin Card
Sorting Test (WCST), Montreal Cognitive Assessment Scale (MOCA), Enhanced Cued Recall (ECR) and Mini Mental
Test (MMT) were used for neurocognitive evaluation. All tests were repeated after one night PAP therapy in OHS
and OSAS groups.
Results: OHS patients had the lowest scores of physical (PF) and social functioning (SF) in SF-36. The total number
of persistent errors and incorrect answers were the highest in OHS group in WCST. The scores of MOCA, ECR and
MMT were lower; depression and anxiety scores were higher in OHS group than in controls (p = 0,00). There was a
significant increase in the completed categories in OHS after PAP therapy (p = 0,03). There were also significant
increases in MOCA, ECR and MMT scores and significant decreases in depression and anxiety scores with respect to
PAP therapy.
Conclusions: Cognitive dysfunction, depression and anxiety are important under-recognized comorbidities in OHS.
It is suggested that short term PAP therapy had positive effects on neurocognitive functions, depression and
anxiety but further multicentre, prospective studies with large number of cases are needed to evaluate the effect of
long term PAP therapy on these parameters.
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Background
Obesity is a global health problem with increasing preva-
lence. It is related to severe economic burden on health
care services due to high mortality and morbidity [1].
Obesity Hypoventilation Syndrome is defined as a com-
bination of obesity (BMI ≥ 30 kg/m2) and daytime hyper-
capnia in arterial blood gas analysis (PaCO2 > 45 mmHg)
without other pathologies that cause hypoventilation [2].
The pathophysiology of OHS includes increased mechanic
load on respiratory system, blunting of ventilatory drive,
and inadequate chemoreceptor response to hypercarbia
and hypoxemia. The hypercapnia and hypoxia induce
pathologic effects that further worsen sleep-related
breathing, resulting in a slowly progressive worsening of
disease.
Comorbid diseases, especially the cardiac ones, are
frequent in OHS. Neurocognitive dysfunction and psy-
chiatric disorders such as depression and anxiety are
some of probable comorbid diseases. Neurocognitive
impairment is associated with limited creativity, work
performance, quality of life, self esteem, and
psychosocial functioning [3]. Psychiatric symptoms and
cognitive dysfunction often occur in patients with
chronic respiratory diseases such as asthma and
chronic obstructive pulmonary disease (COPD) [4].
Cognitive dyfunctions, depression and anxiety are also
frequent in Obstructive Sleep Apnea Syndrome (OSAS)
patients [5–8]. OHS and OSAS have similar clinical
characteristics including obesity, sleepiness and snor-
ing. While there are many studies evaluating the role of
OSAS or obesity on neurocognitive functions and psy-
chiatric disorders, there are no studies evaluating these
parameters in OHS patients. As a major component of
OHS, obesity is related to behavioral problems, depres-
sion and anxiety [9–11]. Morbidly obese patients are
described as depressed, anxious and with impaired
quality of life. These people are exposed to physical,
psychological and social consequences of obesity and
they have high risk for psychiatric disorders [12].
Positive airway pressure therapy is first line therapy in
both OHS and OSAS. While there are many studies
evaluating the role of PAP therapy on neurocognitive
functions and psychiatric disorders in OSAS patients
[13–16], there are no studies evaluating the role of PAP
therapy on neurocognitive functions in OHS patients.
The aim of this study is to evaluate the quality of life,
presence of neurocognitive dysfunctions, depression and
anxiety and the effect of positive airway pressure (PAP)
therapy on these parameters in OHS patients.
Methods
Study population
Ten healthy normal and obese controls, 10 OHS and 10
OSAS patients were included in the study between
October 2014 and December 2015. It was a hospital
based study.
Inclusion criteria
Individuals who were advised to use PAP therapy for the
diagnoses of OHS and OSAS were included in the study.
All patients were evaluated by PSG and arterial blood gas
analysis (ABG). Isolated OHS and OSAS patients were
included, while overlap cases with both hypercapnia and
obstructive sleep apnea findings at PSG were excluded.
Healthy normal and obese controls with snoring and
increased Epworth scale also underwent PSG and ABG
analysis for excluding OSAS and OHS. All participants
were informed about the study aim and gave written in-
formed consent.
Exclusion criteria
Individuals with acute decompansated OHS, age <
18 years, barriers to PAP therapy due to facial deformities,
neurologic and psychiatric disorders and hypercapnic dis-
eases such as chronic obstructive pulmonary disease,
respiratory failure related to chest wall deformities and
neuromuscular disease were excluded from the study.
Study plan
There were ten healthy normal and ten obese controls,
10 OHS and 10 OSAS patients, totally forty participants
in the study. Initially, demographic characteristics of the
participants including gender, BMI, smoking history and
Epworth Sleepiness Scale (ESS) results were recorded.
Quality of life was assessed by Short form-36 (SF-36).
Depression and anxiety questionnaires and neurocognitive
assessment tests were performed in the morning by psy-
chologists. Wisconsin Card Sorting Test (WCST), Montreal
Cognitive Assessment Scale (MOCA), Enhanced Cued
Recall (ECR) and Mini Mental Test (MMT) were used for
neurocognitive evaluation.
Patients with OHS and OSAS underwent PAP therapy
in the same day. Continuous positive airway pressure
(CPAP) therapy was used for OSAS patients while bi-
level continuous positive airway pressure (BIPAP) ther-
apy was used for OHS patients. Mean efficient CPAP
pressure was 6 or 7 cm H20 in OSAS patients. For
BIPAP therapy, inspiratory (IPAP) and expiratory (EPAP)
pressures were 15 cmH2O and 5 cmH2O respectively.
All tests were repeated after one night PAP therapy in
these groups.
* Short form-36 (SF-36)
The SF-36 is widely used to measure health status and
quality of life. It includes eight domains as follows: physical
functioning (PF), role limitations due to physical problems
(RP), bodily pain (BP), general health perception (GH), en-
ergy/vitality (VT), role limitations due to emotional
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problems (RE), social functioning (SF), and mental health
(MH). Each domain is transformed onto a score from 0
(worst possible health) to 100 (best possible health).
* Montreal cognitive assessment scale-MOCA
MOCA assesses different cognitive dimensions including
orientation, attention, concentration, executive func-
tions, memory, language, and visual-spatial skills. Total
score of MOCA < 26 points is considered to be cogni-
tive dysfunction.
* Beck depression scale-BDS
The Beck Depression Inventory is a self-rating scale for
measuring symptoms of depression. The lowest score is 0
and the highest score is 63. Twelve points and above is
considered to be depression.
* State-trade anxiety inventory, STAI 1-2
STAI 1 indicates how individuals feel at a given moment
or condition. STAI 2 determines how individuals feel re-
gardless of their conditions. The lowest score is 20 and
the highest one of the scale is 80 for both state and trade
anxiety inventory. The increase in test scores correlated
with severity of anxiety.
* Mini mental test (MMT)
Mini Mental Test is a tool that can be easily applied.
MMT evaluates the 5 main functions including orienta-
tion, registration memory, attention and recall, calculation
and language. The highest score of the test is 30. Total
score of MMT ≥ 24 points is considered to be normal,
while <24 points as cognitive dysfunction.
Statistical analyses
All statistical analyses were performed using IBM SPSS for
Windows version 20.0 (SPSS, Chicago, IL, USA).
Kolmogorov-Smirnov Tests were used to test the normality
of data distribution. Continuous variables were expressed
as median (25.percentile-75.percentile), and categorical var-
iables were expressed as counts (percentage). Comparisons
of continuous paired variables were performed using the
Wilcoxon t test and comparisons of continuous variables
between groups were performed using the Kruskal Wallis
Analysis of Variance and Dunn’s Post Hoc Test. Compari-
sons of categorical variables between the groups were
performed using the Yates’s and Monte Carlo chisquare
test. A two-sided p < 0.05 was considered statistically
significant.
Results
There were 25 females (62.5 %) and 15 males (37.5 %),
totally 40 individuals. The distrubition of the gender ac-
cording to groups is shown in Fig. 1. The mean age was
45.7 ± 14.6 years and the mean BMI was 38.03 ± 10.3 kg/
m2. The mean age was lower in control groups than in
OHS and OSAS groups and the difference was signifi-
cant (p = 0.003). However, the mean ages of OHS and
OSAS groups were similar. BMI was similar in obese
control, OHS and OSAS groups. A significant difference
of Epworth score was found between healthy normal
controls and patient groups (OHS and OSAS) (p = 0.007
and p = 0.002). There was also a significant difference of
Epworth score between obese controls and OSAS group
(p = 0.027). The median of smoking pack/years in OHS
group was higher than in other groups (Table 1).
There were significant differences in SF-36 subscales
including physical functioning (PF) (p = 0.03), general
perception of health (GH) (p = 0,03) and social function-
ing (SF) (p = 0,04) between the groups. OHS patients
had the lowest scores of PF and SF (Table 2).
The number of completed categories and correct
answers was the lowest in OHS group in WCST. Fur-
thermore, the total number of persistent errors and
incorrect answers was the highest in OHS group. There
were significant differences in the total number of com-
pleted categories, correct numbers, persistent errors and
percentage of conceptual level responses among the
groups. The numbers of completed categories were sig-
nificantly lower in OHS and OSAS than in healthy nor-
mal controls (p = 0.01; p = 0.03) (Table 3).
The scores of MOCA and ECR tests were the lowest
in OHS group. MMT scores were lower in both OHS
and OSAS groups than in controls and the difference
was statistically significant (p = 0.00) (Table 4). Nearly
half of the OHS patients had cognitive dysfunction ac-
cording to cut off value (MMT < 24 points) (Fig. 2).
There was a significant difference in MMT score in sub-
group analysis (p = 0.00). While there was no significant
difference in MMT score in OHS and OSAS groups, it was
found that the difference was statistically significant be-
tween healthy normal control and OHS group (p = 0.008).
Also, subgroup analyses of MOCA and ECR showed sig-
nificant differences between OHS and control groups
(MOCA: OHS-Healthy normal control p = 0.003; OHS-
Obese control p = 0.003; ECR: OHS-Healthy normal con-
trol p = 0.002; OHS-Obese control p = 0.007). There were
significant differences in MOCA and ECR scores between
OSAS and control groups (MOCA: OSAS- Healthy normal
control p = 0.047; OSAS-Obese control p = 0.043; ECR:
OSAS- Healthy normal control p = 0.001; OSAS-Obese
control p = 0.004).
Depression and anxiety scores were higher in OHS
group than in controls (p = 0.00) (Table 5). The cut off
values for depression and anxiety were respectively 12
points and 44 points. All of the participants had high
depression scores in both OHS and OSAS groups (Fig. 3).
Furthermore, the percentage of state and trade anxiety
was the highest in OHS group (Fig. 4). While there was
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no significant difference in Beck Depression score in OHS
and OSAS groups at subgroup analysis, it was found that
the difference was statistically significant between OHS
and control groups (OHS- Healthy normal control, p =
0.014; OHS-Obese control, p = 0.005). Subgroup analysis
of STAI-1 showed significant differences between OHS
and control groups (OHS-Healthy normal control p =
0.025; OHS- Obese control p = 0.007). In addition, there
were significant differences in STAI-2 scores between
OHS and obese control group (p = 0.033) and OSAS and
obese controls (p = 0.04).
The number of completed categories in WCST was
increased after one night PAP in both OHS and OSAS
groups (p = 0.03) (Table 6). In addition, there were
significant increases in MOCA (p = 0.01), ECR (p =
0.01) and MMT (p = 0.04) scores and significant
decreases in depression (p = 0.01) and anxiety scores
(STAI 1 p = 0.05; STAI 2 p = 0.02) with respect to PAP
therapy (Tables 7 and 8).
Discussion
This study demonstrated that OHS patients had the
lowest scores of physical (PF) and social functioning
(SF) in SF-36. The total number of persistent errors
and incorrect answers was the highest in OHS group in
WCST. The scores of MOCA, ECR and MMT were
lower and depression/anxiety scores were higher in
OHS patients than controls. There was a significant in-
crease in completed categories in WCST after PAP
therapy. Furthermore, there were significant increases
in MOCA, ECR and MMT scores and significant
Fig. 1 The distribution of gender according to groups (%)
Table 1 Demographic characteristics of the groups
Group Age BMI Smoking pack/years Epworth score
Healthy normal control (N = 10) Median 31.5a 25.6a,b,c 0,5a 1a,b
Percentile 25 26 22.4 0 0
75 51.25 27.2 7 4
Obese control (N = 10) Median 38b 39.6a 4b 1.5
Percentile 25 27.25 37.04 0 1
75 47.75 48.05 13.5 6
OHS (N = 10) Median 56.5a, b 44.97b 18a,b,c 10a
Percentile 25 51.75 40,2 0 3.75
75 64 54.7 67.5 15.25
OSAS (N = 10) Median 52 37.6c 3.5c 9.5b
Percentile 25 35.75 32.7 0 5.5
75 59.5 41.96 26.25 18.5
Comparison of groups: Statistically significant differences (p < 0.05) were summarized. Age: a. Healthy normal control and OHS, p = 0.015 b. Obese control and
OHS, p = 0.013
BMI: a. Healthy normal control and obese control, p = 0.04 b. Healthy normal control and OHS, p = 0.001 c. Healthy normal control and OSAS, p = 0.001
Smoking package: a. Healthy normal control and OHS, p = 0.001 b. Obese control and OHS, p = 0.023 c. OHS and OSAS, p = 0.032
Epworth score: a. Healthy normal control and OHS, p = 0.007 b. Healthy normal control and OSAS, p = 0.002 c. Obese control and OSAS, p = 0.027
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decreases in depression and anxiety scores with respect
to PAP therapy.
The Obesity Hypoventilation Syndrome is a chronic sys-
temic disease characterized by comorbidities resulting in
high mortality and morbidity rates. Respiratory, metabolic,
hormonal and cardiovascular comorbidities are related
with decreased daily activities and quality of life [17].
The prevalence of OHS in general population is unclear
and data about OHS prevalence are mostly described in
OSAS patients. It is estimated that prevalence ranges from
10 % to 38 % [18–20]. In a retrospective study, coexistence
of OSAS and OHS were identified in 11% of patients [21].
Hypoventilation was found in 31 % of the obese subjects
who did not have other reasons for hypercapnia [22]. It is
Table 2 The results of SF-36 according to groups

















































































Comparison of groups: Statistically significant differences (p < 0.05) were summarized
PF: a. Healthy normal control and OHS, p = 0.03
SF: a. Healthy normal control and OHS, p = 0.04
GH: a. Healthy normal control and obese control, p = 0.03
PF: Physical functioning; RP: Role limitation due to physical problems; BP: Bodily pain; GH: General perception of health; VT: Energy and vitality; SF: Social
functioning; RE: Role limitation due to emotional problems; MH: Mental health
Table 3 Winconsin Cart Sorting Test results of the groups

















































































Comparison of groups: Statistically significant differences (p < 0.05) were summarized
The number of completed categories: a. Healthy normal control and OHS, p = 0.01 b. Healthy normal control and OSAS, p = 0.03
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suggested that OHS is expected to increase in near future
depending on increasing obesity prevalence worldwide. In
this study, OHS and OSAS patients were evaluated by
polysomnography and arterial blood gas analysis. Isolated
OHS and OSAS patients were enrolled while overlap pa-
tients were excluded from the study.
The Epworth Scale is a validated queastionnaire asses-
sing the sleepiness of the patient. In Hida et al.’s study,
the Epworth score was found to be worse in untreated
OHS and OSAS patients than in matched healthy sub-
jects [23]. Also Epworth scores of OHS patients were
worse than in age and BMI matched OSAS group [21].
Similar to literature, the Epworth score was the highest
in OHS group and the difference was significant (p =
0,007) in our study. On the other hand, there were no
significant differences in age, BMI and Epworth scores
between OHS and OSAS groups.
The median of smoking pack/years in OHS group was
higher than in other groups. The half of the participants
in OHS and OSAS were male while this ratio was 20 %
for healthy normal controls and 30 % for obese controls.
Smoking is more prevalent in men than in women in
our country. As result, the difference might be explained
by the age and gender distribution of the groups.
The hypercapnia and hypoxia induce pathologic effects
that further worsen sleep-related breathing, resulting in a
slowly progressive worsening of OHS. Health care costs are
high and comorbidities are common in untreated patients.
Psychiatric disorders and neurocognitive dysfunction are
probable adversely affected conditions. Neurocognitive im-
pairment restricts creativity, work performance, quality of
life, self esteem, and psychosocial functioning [3]. Excessive
sleepiness and altered circadian rhythms may negatively
affect ability to learn, employment, interpersonal relations,
and quality of life [24].
The SF-36 is widely used to measure health status and
quality of life. The test is not specific to any illness or
age group. The effects of sleep disorders on the quality
of life have been documented in the literature [24].
However, the studies assessing quality of life in OHS
patients are limited [21–23]. Untreated OHS and OSAS
patients had worse results compared to matched healthy
subjects on SF-36 subscales such as physical functioning,
role limitations due to physical problems, general health
Table 4 Comparison of neurocognitive assessment test scores among the groups





































Comparison of groups: Statistically significant differences (p < 0.05) were summarized
MOCA: a. Healthy normal control and OHS, p = 0.003 b. Obese control and OHS, p = 0.003 c. Healthy normal control and OSAS, p = 0.047 d. Obese control and
OSAS, p = 0.043
ECR: a. Healthy normal control and OHS, p = 0.002 b. Obese control and OHS, p = 0.007 c. Healthy normal control and OSAS, p = 0.001 d. Obese control and
OSAS, p = 0.004
MMT: a. Healthy normal control and OHS, p = 0.008 b. Healthy normal control and OSAS, p = 0.003 c. Obese control and OSAS, p = 0.035
Fig. 2 Comparison of cognitive dysfunction according to MMT scores among the groups (%)
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perception, energy/vitality, role limitations due to emotional
problems and social functioning [21]. SF-36 subscales such
as physical functioning, role limitations due to physical
problems, body pain, social functioning and role limitations
due to emotional problems were the worst in OHS group
in our study. The difference in physical and social function-
ing scores between OHS and healthy normal control was
significant. Although these findings are consistent with the
literature, the difference between healthy normal controls
and OHS group may be affected by the lower mean age of
control group. Therefore, it is suggested that prospective
studies with large number of age matched cases are needed
to support this findings.
Psychiatric comorbidities have an important role on
quality of life [4]. Many authors draw attention to relation-
ship between mental health and disease progression and
treatment efficacy [25, 26]. It is reported that severity of
the comorbidities is frequent in the coexistence of depres-
sion [27]. The existence of psychiatric symptoms in pa-
tients with respiratory diseases is higher compared to the
controls in several studies [4, 25, 28, 29]. Depression and
anxiety are common also in OSAS patients [5].
Obesity as a major component of the OHS has been
investigated in many studies [9, 10]. It is reported that
obesity is associated with behavioral problems, depression
and anxiety. The symptoms of depression and anxiety are
high in obese patients before the bariatric surgery [10].
Obese adolescents suffer from body dissatisfaction, anhe-
donia, low self-esteem, and depressive symptoms more
often than normal-weight persons [11]. Morbidly obese
patients are described as depressed, anxious, having poor
impulse control, low self-esteem, and impaired quality of
life. These people are exposed to physical, psychological
and social consequences of obesity and they have high risk
for psychiatric disorders [12].
To our knowledge, there are no studies evaluating
depression and anxiety in OHS patients. All patients in
OHS and OSAS groups had depressive symptoms in our
study. Increased scores of Beck Depression Scale are
correlated with the severity of depression. Median de-
pression scores of healthy control, obese control, OHS
and OSAS patients were 12 points, 7 points, 26 points
and 25 points respectively in this study. However, as an
interesting result, half of the healthy normal controls
Table 5 Comparison of depression and anxiety scores (state and idem) of the groups





































Comparison of groups: Statistically significant differences (p < 0.05) were summarized
BDS: a. Healthy normal control and OHS, p = 0.014 b. Obese control and OHS, p = 0.005 c. Obese control and OSAS, p = 0.023
STAI-1: a. Healthy normal control and OHS, p = 0.025 b. Obese control and OHS, p = 0.007 c. Healthy normal control and OSAS, p = 0.024 d. Obese control and
OSAS, p = 0.007
STAI-2: a. Obese control and OHS, p = 0.033 b. Obese control and OSAS, p = 0.04
Fig. 3 The distribution of depression among the groups (%)
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had depression according to cut off value since the
median score of the healthy controls was equal to
that of depression. It is suggested that high percent-
age of depression in healthy controls might be
explained by female predominance and overdiagnosis
of depression due to using a cut-off value instead of
real scores.
State and trade anxiety scores were also highest in OHS
group. While the depression and anxiety scores of OHS
and OSAS groups were similar, there were significant dif-
ferences in these parameters between OHS group and
both normal and obese controls. Although there is no dif-
ference in BMI between obese controls and OHS patients,
increased depression and anxiety scores of OHS patients
suggest the role of various factors in addition to obesity. It
is thought that OHS patients are required to assess the de-
velopment of psychiatric disorders.
As in psychiatric disorders, cognitive function can be
affected by chronic diseases. Although the prevalence of
cognitive dysfunction in patients with OSAS is not fully
known, cognitive dysfunctions including attention and
memory impairment have been reported in the literature
[6–8]. Various mechanisms have been identified in devel-
opment of cognitive dysfunction in OSAS [6, 7]. The first
of these mechanisms is excessive daytime sleepiness.
Sleepiness plays a role in the development of cognitive
dysfunction, especially in attention and executive func-
tions [30, 31]. A second possible mechanism is intermit-
tant hypoxemia [32]. Hypoxemia is found to be associated
with reduced attention and processing speed [14, 33]. It is
reported that cognitive functions are worse in hypoxemic
OSAS patients than in non-hypoxemic ones [34]. Also the
individual factors such as age and obesity have an import-
ant effect on cognitive dysfunction [35–37].
Fig. 4 Presence of state and trade anxiety among the groups (%)
Table 6 The effect of PAP therapy on WCST scores in OHS and OSAS patients
OHS OSAS
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It is suggested that intermittant hypoxemia, daytime
sleepiness and obesity may have an effect on neurocogni-
tive dysfunction in OHS patients. While there are many
studies evaluating the role of OSAS and obesity on neuro-
cognitive functions, there is no study evaluating this rela-
tionship in OHS patients. In the present study,
neurocognitive functions have been assessed by using vari-
ous tests such as WCST, MMT, MOCA and ECR.
MMT is one of the most frequently used tests. It is re-
ported that MMT was lower in OSAS than in controls in
Kanbay et al.’s study [38]. In baseline assessment of this
study, MMT scores were found to be lower in both OHS
and OSAS groups than in controls and the difference was
statistically significant (p = 0.00). Nearly fifty five percent of
the OHS patients had cognitive dysfunction according to
cut-off value (MMT< 24 points). As similar to MMT,
MOCA and ECR were also significantly lower in OHS and
OSAS patients with respect to controls. However, the
results of MOCA, ECR and MMT were similar in both
patient groups. The numbers of completed categories and
correct answers were the lowest in OHS group in WCST.
Also the total number of persistent errors and incorrect
answers were the highest in OHS group. Perseveration
means to insist on the same behavior even though it is said
that it was wrong. Despite our small number of cases,
the similar results of different neurocognitive tests
supporting each others are remarkable. Individuals
with cognitive impairment have a tendecy to
misunderstanding the recommendations of the doctor
[4]. Therefore, a correct and effective treatment of
OHS should start with a multidisciplinary approach
and all patients with OHS should be assessed for
neurologic and psychiatric disorders.
Positive airway pressure therapy is the first line ther-
apy in both OHS and OSAS [39, 40]. The role of PAP
therapy on neurocognitive functions in OSAS patients
has been evaluated in literature [7, 13], but there is no
study assessing this relation in OHS patients. The results
of these studies are controversial due to different sam-
pling and methodology. While there was no significant
difference in cognitive functions before and after PAP
therapy [7, 41], some of these studies reported an im-
provement in attention, executive functions and short
memory after CPAP therapy [14–16].
One of the main reasons for the different outcomes is
the variable duration of PAP therapy (min: 1 week and
max: 12 months). Bardwell et al. reported that there was
a cognitive improvement after one week CPAP therapy
[14]. There was an improvement in attention and speed
of motor skills after CPAP therapy but the results were
not different after 15 days or 4 months [16]. A positive
relationship between the duration of PAP therapy and
continuous improvement in attention was only shown in
Munoz et al.'s study [15]. The shortest duration of PAP
therapy in literature was one night. Our clinical observa-
tions and experiences showed that OHS patients were
Table 7 The effect of PAP therapy on MOCA, ECR and MMT scores in OHS and OSAS patients
OHS OSAS





































Table 8 The effect of PAP therapy on depression and anxiety scores in OHS and OSAS patients
OHS OSAS
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unhappy, sleepy, hopeless and reluctant to therapy. They
had limited verbal communication due to sleepiness dur-
ing the hospitalization. It was observed that they had a
positive attitude about the management after even one
night PAP therapy. Furthermore, they were hopeful and
willing to live since they had a good sleep. This experi-
ence was the cornerstone of our study. So we aimed to
evaluate the acute effects of PAP therapy on neurocogni-
tive functions.
There were significant increases in MOCA, ECR MMT,
and WCST scores after one night PAP therapy. However,
only one item (the number of completed categories) of the
WCST had a significant improvement after treatment. It
might be explained by the relatively small size of our study
population and short duration of PAP therapy. In addition,
there were significant decreases in depression and anxiety
scores with respect to PAP therapy. These findings suggest
that PAP therapy has positive effects on neurocognitive
functions and psychiatric symptoms even in a short
period. However, these are chronic disorders and we think
that positive results after one night PAP therapy do not
fully reflect the improvement. It is suggested that further
prospective studies with large number of cases are needed
to evaluate the effect of long term PAP therapy on these
parameters. It is planned to control neurocognitive assess-
ment in the sixth month of the PAP therapy in OHS and
OSAS groups for follow up.
To our knowledge, this is the first study evaluating the
neurocognitive functions, depression/anxiety and the role
of PAP therapy on these parameters in OHS patients. Be-
side this, the limited size of the patient groups, the presence
of younger control group and the assessment of short term
effects of PAP therapy are the limitations of this study.
Conclusions
Cognitive dysfunction, decreased quality of life, depres-
sion, and anxiety are important recognized comorbidities
in OHS. The scores of MOCA, ECR and MMT are lower
in OHS patients than in controls. The depression and anx-
iety scores of OHS patients are higher than in controls.
These findings suggest that the management of OHS
needs a multidisciplinary approach. It is suggested that
short term PAP therapy can have positive effects on neu-
rocognitive functions, depression and anxiety but further
multicentre, prospective studies with large number of
cases are needed to evaluate the effect of long term PAP
therapy on these parameters.
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